Literature DB >> 8958597

Smoking, smoking withdrawal and schizophrenia: case reports and a review of the literature.

G W Dalack1, J H Meador-Woodruff.   

Abstract

Our efforts to study and understand the complex clinical, behavioral, neurochemical and neuroanatomical manifestations of the schizophrenias are plagued by the heterogeneity of findings, and lack of ability to define subtypes within the syndrome. Theoretically, a behavior associated with schizophrenia among a majority of those affected might provide more broadly applicable information about the illness. Cigarette smoking represents such a behavior. Herein we present an overview of evidence linking cigarette smoking and schizophrenia, and describe three cases suggesting that nicotine withdrawal leads to an exacerbation of schizophrenic symptoms.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8958597     DOI: 10.1016/s0920-9964(96)80441-5

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  28 in total

Review 1.  Microarray technology and its application on nicotine research.

Authors:  Ming D Li; Ozien Konu; Justin K Kane; Kevin G Becker
Journal:  Mol Neurobiol       Date:  2002-06       Impact factor: 5.590

2.  A double-blind randomized clinical trial of different doses of transdermal nicotine patch for smoking reduction and cessation in long-term hospitalized schizophrenic patients.

Authors:  Hsing-Kang Chen; Tsuo-Hung Lan; Bo-Jian Wu
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-06-23       Impact factor: 5.270

3.  Predictors of smoking reduction outcomes in a sample of 287 patients with schizophrenia spectrum disorders.

Authors:  Bo-Jian Wu; Tsuo-Hung Lan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-08-27       Impact factor: 5.270

Review 4.  Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism?

Authors:  Robert M Roth; Mary F Brunette; Alan I Green
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

Review 5.  Pharmacotherapy for schizophrenia and co-occurring substance use disorders.

Authors:  Alan I Green
Journal:  Neurotox Res       Date:  2007-01       Impact factor: 3.911

Review 6.  Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Authors:  Ann Olincy; Karen E Stevens
Journal:  Biochem Pharmacol       Date:  2007-07-17       Impact factor: 5.858

Review 7.  Tobacco use among individuals with schizophrenia: what role has the tobacco industry played?

Authors:  Judith J Prochaska; Sharon M Hall; Lisa A Bero
Journal:  Schizophr Bull       Date:  2007-11-05       Impact factor: 9.306

8.  N-methyl-D-aspartate receptor and calbindin-containing neurons in the anterior cingulate cortex in schizophrenia and bipolar disorder.

Authors:  Tsung-Ung W Woo; Kevin Shrestha; Dorian Lamb; Martin M Minns; Francine M Benes
Journal:  Biol Psychiatry       Date:  2008-06-30       Impact factor: 13.382

Review 9.  Subtypes of nicotinic acetylcholine receptors in nicotine reward, dependence, and withdrawal: evidence from genetically modified mice.

Authors:  Christie D Fowler; Michael A Arends; Paul J Kenny
Journal:  Behav Pharmacol       Date:  2008-09       Impact factor: 2.293

10.  Cognitive performance and cigarette smoking in first-episode psychosis.

Authors:  Arantzazu Zabala; José Ignacio Eguiluz; Rafael Segarra; Sonsoles Enjuto; Jesús Ezcurra; Ana González Pinto; Miguel Gutiérrez
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-06-26       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.